GeroinC, GandolfiM, BrunoV, et al.: Integrated approach for pain management in Parkinson disease. Curr Neurol Neurosci Rep, 2016; 16:28.
3.
ForsaaEB, LarsenJP, Wentzel-LarsenT, et al.: A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol, 2010; 67:996–1001.
4.
FenelonG, MahieuxF, HuonR, ZieglerM: Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain, 2000; 123 (Pt 4):733–745.
5.
ZesiewiczTA, SullivanKL, ArnulfI, et al.: Practice parameter: Treatment of nonmotor symptoms of Parkinson disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2010; 74:924–931.
6.
FernandezHH, FriedmanJH, JacquesC, RosenfeldM: Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord, 1999; 14:484–487.
7.
MorganteL, EpifanioA, SpinaE, et al.: Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci, 2002; 23Suppl 2:S89–S90.
8.
JuncosJL, RobertsVJ, EvattML, et al.: Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord, 2004; 19:29–35.
9.
PollakP, TisonF, RascolO, et al.: Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry, 2004; 75:689–695.
10.
MiyasakiJM, ShannonK, VoonV, et al.: Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2006; 66:996–1002.
11.
WeintraubD, ChiangC, KimHM, et al.: Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol, 2016; 73:535–541.
12.
CummingsJ, IsaacsonS, MillsR, et al.: Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet, 2014; 383:533–540.
13.
SeppiK, WeintraubD, CoelhoM, et al.: The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord, 2011; 26Suppl 3:S42–S80.
14.
ConnollyBS, LangAE: Pharmacological treatment of Parkinson disease: A review. JAMA, 2014; 311:1670–1683.
15.
AdlerCH, CavinessJN, HentzJG, et al.: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord, 2003; 18:287–293.
16.
GjerstadMD, AlvesG, Wentzel-LarsenT, et al.: Excessive daytime sleepiness in Parkinson disease: Is it the drugs or the disease?. Neurology, 2006; 67:853–858.
17.
HobsonDE, LangAE, MartinWR, et al.: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group. JAMA, 2002:287:455–463.
18.
MenzaM, DobkinRD, MarinH, et al.: A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009; 72:886–892.
19.
HauserRA, ZesiewiczTA: Sertraline for the treatment of depression in Parkinson's disease. Mov Disord, 1997; 12:756–759.
20.
EmreM, AarslandD, AlbaneseA, et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 2004; 351:2509–2518.
21.
SrivanitchapoomP, PandeyS, HallettM: Drooling in Parkinson's disease: A review. Parkinsonism Relat Disord, 2014; 20:1109–1118.
22.
ChouKL, KoeppeRA, BohnenNI: Rhinorrhea: A common nondopaminergic feature of Parkinson's disease. Mov Disord, 2011; 26:320–323.
23.
ThomsenTR, GalpernWR, AsanteA, et al.: Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord, 2007; 22:2268–2273.
24.
HysonHC, JohnsonAM, JogMS: Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study. Mov Disord, 2002; 17:1318–1320.
